Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $340.56 Average PT from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $340.5556.

Several brokerages have weighed in on KRYS. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Citigroup increased their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 5th. Wolfe Research assumed coverage on Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Finally, Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. acquired a new position in Krystal Biotech during the 2nd quarter valued at about $337,000. GAMMA Investing LLC lifted its stake in shares of Krystal Biotech by 16.3% in the 2nd quarter. GAMMA Investing LLC now owns 998 shares of the company’s stock worth $371,000 after acquiring an additional 140 shares during the period. Harbor Investment Advisory LLC bought a new position in shares of Krystal Biotech in the second quarter valued at approximately $92,000. Versant Capital Management Inc increased its stake in shares of Krystal Biotech by 189.2% during the second quarter. Versant Capital Management Inc now owns 214 shares of the company’s stock valued at $80,000 after acquiring an additional 140 shares during the period. Finally, Pacer Advisors Inc. increased its stake in shares of Krystal Biotech by 48.8% during the first quarter. Pacer Advisors Inc. now owns 2,547 shares of the company’s stock valued at $658,000 after acquiring an additional 835 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded down $5.43 during midday trading on Friday, hitting $365.81. 363,546 shares of the company’s stock traded hands, compared to its average volume of 350,365. The firm’s fifty day moving average price is $325.15 and its two-hundred day moving average price is $286.04. Krystal Biotech has a twelve month low of $130.50 and a twelve month high of $382.54. The company has a market cap of $10.78 billion, a PE ratio of 48.91 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. As a group, equities research analysts anticipate that Krystal Biotech will post 7.66 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.